Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma

Kalpathy-Cramer, J; Chandra, V; Da, X; Ou, YM; Emblem, KE; Muzikansky, A; Cai, XZ; Douw, L; Evans, JG; Dietrich, J; Chi, AS; Wen, PY; Stufflebeam, S; Rosen, B; Duda, DG; Jain, RK; Batchelor, TT; Gerstner, ER

Gerstner, ER (reprint author), Massachusetts Gen Hosp, Ctr Canc, Stephen E & Catherine Pappas Ctr Neurooncol, Yawkey 9E,55 Fruit St, Boston, MA 02114 USA.

JOURNAL OF NEURO-ONCOLOGY, 2017; 131 (3): 603

Abstract

Targeting tumor angiogenesis is a potential therapeutic strategy for glioblastoma because of its high vascularization. Tivozanib is an oral pan-VEGF r......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索